Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Fig. 3

OS Analyses By Post HD IL-2 Therapy. a and b Kaplan-Meier plots of overall survival in patients who progress on HD IL-2 therapy depending on receipt of CTLA-4/PD-1 checkpoint inhibitor therapy (a) or BRAF/MEK inhibitors (b). CTLA-4/PD-1 checkpoint inhibitor therapy in HD IL-2 failures prolongs survival compared to untreated patients; with similar 1−/2−/3- year survival rates as those treated independently. BRAF/MEK inhibitor therapy in HD IL-2 failures produces similar PFS benefits but overall survival is not significantly improved

Back to article page